Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Translational research 1

4852 - Identification of biological axes associated with stage II/III CRC recurrence risk and outcome after adjuvant therapy revealed a T-effector-independent prognostic role for granzyme B.

Date

20 Oct 2018

Session

Poster Discussion session - Translational research 1

Topics

Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Meghna Das Thakur

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

M. Das Thakur1, A. Udyavar1, T. Sandmann2, C. Li1, L.J.W. Bosch3, W. O'Gorman1, Y. Li1, A. Au-Yeung1, C. Takahashi1, R. Bourgon1, A. Daemen1, P. Hegde1, C. Bais1

Author affiliations

  • 1 Oncology Bomarker Development, Genentech Inc. - Roche - USA, 94080 - South San Francisco/US
  • 2 Computational Biologist, Denali Therapeutics, SSF/US
  • 3 Translational Gastrointestinal Oncology Group Department Of Pathology, Netherlands Cancer Institute, Amsterdam/NL
More

Resources

Abstract 4852

Background

CRC continues to be a leading cause of cancer-related deaths, with 5-year 5% survival rate in metastatic patients. In early disease, adjuvant chemotherapy is becoming common practice to improve cure rates for patients with high-risk (hr) stage II primary disease as per the AJCC/UICC-TNM classification. However, the specificity of risk assessment is suboptimal, as all HR pts receive aggressive chemotherapy but only a minority of them are expected to have recurrences. Here, we aimed to explore biological pathways in stage II/III CRC associated with recurrence and outcome.

Methods

1062 FFPE archival tumors from the AVANT phase III trial were profiled by nanostring, Avant was a prospective 3-arm randomized phase 3 clinical trial, in histologically confirmed stage 3 or hr (as defined by AJCC) stage 2 CRC, with DFS as a primary endpoint. Results were all validated in TCGA and GSE39582.

Results

Retrospective analysis of the AVANT trial uncovered a prognostic signature containing 3 biological axes: stromal, proliferative, and immune. This signature outperformed published signatures such as CMS subtypes and diagnostic signatures like OncotypeDx in an independent data set. High GZMB expression alone had a significant prognostic impact in AVANT and GSE39582 (OS Cox model HR 0.46 and p-value 0.000201) while other individual T-effector genes were not prognostic or less prognostic. Tumor FACS experiments identified immune-cell types expressing GZMB that are low for PD1 and could drive the-effector independent prognostic role for GZMB in CRC.

Conclusions

The results described herein furthers our understanding of the biological bases underlying stage II/III CRC disease progression and provide scientific rationale for future HR stratification and targeted treatment evaluation in biomarker defined subpopulations of resectable hr CRC patients.

Clinical trial identification

NCT00112918.

Legal entity responsible for the study

Hoffmann-La Roche.

Funding

Hoffmann-La Roche.

Editorial Acknowledgement

Disclosure

M. Das Thakur: Employee: Genentech. A. Udyavar, C. Li, W. O’Gorman, Y. Li, A. Au-Yeung, C. Takahashi, R. Bourgon, A. Daemen, P. Hegde, C. Bais: Employee: Hoffmann-La Roche. T. Sandmann, L.J.W. Bosch: Past employee: Hoffmann-La Roche.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.